Drug Trial Radar · NCT07760155
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Mar 31, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Shanghai Escugen Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
ESG206Drug
Anti-BAFF-R Monoclonal Antibody
ESG206Drug
Anti-BAFF-R Monoclonal Antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- SLE Responder Index (SRI)-4 response rate at Week 25 compared with placeboTime frame: Up to approximately 25 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China
Zhongshan Traditional Chinese Medicine Hospital
Zhongshan, Guangdong, China
Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Liupanshui Shougang Shuigang Hospital
Liupanshui, Guizhou, China
Affiliated Hospital of Hebei Engineering University
Handan, Hebei, China
Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Changde First People's Hospital
Changde, Hunan, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
Loudi Central Hospital
Loudi, Hunan, China
Zhuzhou Central Hospital
Zhuzhou, Hunan, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Zibo Central Hospital
Zibo, Shandong, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Tongji Hospital
Shanghai, Shanghai Municipality, China
Linfen Central Hospital
Linfen, Shanxi, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China
Huzhou Third People's Hospital
Huzhou, Zhejiang, China
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.